Keiretsu Capital

Home
United States
Seattle, WA
Keiretsu Capital

Keiretsu Capital administers funds on behalf of its Limited Partners - the Co-Investment & Opportunities Fund creates a diversified portfolio of companies.

04/27/2026

Virion Therapeutics reports that a single dose of its drug VRON-0200 triggered strong and lasting immune responses against hepatitis B in most chronically infected patients in its Phase 1b study.

Read more: https://www.businesswire.com/news/home/20260222314451/en/Virion-Therapeutics-Reports-Broad-and-Sustained-Anti-HBV-Immunity-Following-a-Single-VRON-0200-Dose-in-the-Majority-of-Chronically-HBV-Infected-Patients-From-its-Phase-1b-Study-at-CROI-2026

04/20/2026

Lungpacer achieves a key commercial milestone as a leading U.S. hospital completes the first AeroPace procedures.

This marks the real-world launch of its FDA-approved transvenous diaphragm neurostimulation system designed to help critically ill, ventilated patients regain independent breathing faster, reduce time on mechanical ventilation, and improve ICU recovery outcomes.

Read more: https://lungpacer.com/lungpacer-achieves-commercial-milestone-as-leading-u-s-hospital-performs-first-aeropace-procedures-to-help-patients-liberate-from-mechanical-ventilation/

04/13/2026

Archax partners with ClearBid Global Markets to support its expansion into the UK and EU, enabling a regulated digital bond trading and data platform that improves transparency, enhances price discovery, and expands institutional access across infrastructure, corporate, and asset-backed markets.
Read More: https://archax.com/insights/clearbid-global-markets-selects-archax-as-partner-for-uk-and-eu-expansion

04/06/2026

Nuvox Therapeutics has received FDA approval to start its Phase II REBORN trial of NanO₂ for recurrent high‑grade glioma. The trial will test if NanO₂ can help tumors respond better to treatment and improve outcomes for patients facing this aggressive form of brain cancer.
Read more: https://tinyurl.com/ms2x9tkv

03/30/2026

Archax partnered with Lloyds Banking Group and Canton Network to complete the UK’s first public blockchain trade using tokenised deposits. A step toward seamless integration of blockchain and traditional finance.
Read more: https://archax.com/insights/lloyds-and-archax-complete-uks-first-public-blockchain-transaction-using-tokenised-deposits

03/23/2026

Combat Medical hits a clinical milestone: the 1st patient in the HIVEC®-HEAT Phase 3 trial completed treatment at Cheltenham Hospital. The study tests HIVEC® therapy as a potential alternative for BCG-unresponsive bladder cancer.

Read more: https://tinyurl.com/4nuvyase

03/16/2026

ARCHAX has partnered with Lloyds Banking Group and the Canton Network to complete the UK’s first public blockchain transaction using tokenised deposits.

READ MORE: https://tinyurl.com/45ejzr5a

03/09/2026

Nuvox Therapeutics announced the acceptance of abstracts on Triple Negative Breast Cancer at two prestigious scientific conventions.

Read More: https://tinyurl.com/5n64rvpw

03/02/2026

UbiQD, founded by Hunter McDaniel, has emerged as a leading deep tech innovator in New Mexico. It is scaling quantum dot science across agriculture, clean energy, and advanced materials. Read more: https://tinyurl.com/mxrjk3d8

02/23/2026

PittMoss has signed an MOU with Shumukh Alezz Group to advance sustainable agriculture across the UAE and GCC. The partnership will explore tech transfer, product trials, and local manufacturing of peat free growing media. Read more: https://tinyurl.com/5n83vvmt

02/16/2026

Spinal Simplicity announced that it has received FDA 510(k) clearance for its next-generation Minuteman G6 MIS Fusion Device, a minimally invasive spinal platform designed to enhance procedural efficiency. Read more: https://tinyurl.com/4eevyyrt

02/09/2026

b.well is shaping the next phase of digital health with OpenAI’s new ChatGPT Health, helping people securely connect medical records, labs, and wellness data to make health information clearer and more actionable. Read more: https://tinyurl.com/4pa4ma85

Address

2815 Eastlake Avenue East, Suite 300
Seattle, WA
98102

Telephone

+12062558870

Website

http://www.keiretsucapital.com/

Alerts

Be the first to know and let us send you an email when Keiretsu Capital posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Keiretsu Capital:

Shortcuts

Want your business to be the top-listed Finance Company in Seattle?